Table 1 –
Distribution of men on AS according to patient and tumour characteristics, by outcome following AS at 5 yr of follow-up
| Variable | Censor or still on AS (N = 7049) | Progression treatment (N = 2061) | Conversion to active treatment without evidence of progression (N = 952) | Watchful waiting (N = 118) | Other cause of death (N = 116) | p value a |
|---|---|---|---|---|---|---|
| Years on AS | 3.3 (1.4–5.8) | 1.4 (1.1–2.5) | 1.6 (1.0–2.7) | 1.7 (1.2–3.1) | 2.3 (1.5–3.4) | <0.01 |
| Year of diagnosis | 2010 (2007–2013) | 2010 (2007–2011) | 2008 (2004–2010) | 2010 (2009–2010) | 2007 (2003–2010) | <0.01 |
| Age at start of AS (yr) | 65 (60–69) | 65 (61–69) | 65 (60–69) | 72 (65–75) | 69 (65–73) | <0.01 |
| PSA at start of AS (ng/ml) | 5.3 (3.9–7.2) | 5.4 (4.2–7.0) | 5.6 (4.2–7.3) | 5.9 (4.5–7.5) | 6.4 (4.2–9.1) | 0.01 |
| Number of biopsy cores with PCa | 1 (1–2) | 1 (1–2) | 1 (1–2) | 1 (1–2) | 1 (1–2) | <0.01 |
AS = active surveillance; PCa = prostate cancer; PSA = prostate-specific antigen.
The median and interquartile ranges are provided for each variable.
a
Kruskal-Wallis rank sum test.